Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

MLA

Leon-Castillo, A., et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315671544&authtype=sso&custid=ns315887.

APA

Leon-Castillo, A., de Boer, S., Powell, M., Mileshkin, L., Mackay, H., Leary, A., Nijman, H., Singh, N., Pollock, P., Bessette, P., Fyles, A., Haie-Meder, C., Smit, V., Edmondson, R., Putter, H., Kitchener, H., Crosbie, E., de Bruyn, M., Nout, R., … Bosse, T. (2020). Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.

Chicago

Leon-Castillo, A, Sm de Boer, Me Powell, Lr Mileshkin, Hj Mackay, A Leary, Hw Nijman, et al. 2020. “Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315671544&authtype=sso&custid=ns315887.